8-K: Theriva Biologics Announces Conversion of Preferred Stock to Common Stock

Theriva Biologics has received notice of conversion of 135,431 shares of Series C Convertible Preferred Stock into 888,072 shares of common stock at a price of $1.22 per share.

Summary

• Theriva Biologics, Inc. received a notice on May 13, 2024, regarding the conversion of preferred stock.
• The holder of 135,431 shares of Series C Convertible Preferred Stock elected to convert their holdings.
• This conversion resulted in the issuance of 888,072 shares of the company's common stock.
• The conversion price was set at $1.22 per share.

Sentiment

Score: 6

Explanation: The document describes a routine financial transaction. It is neither particularly positive nor negative, but a normal part of the company's financial operations.

Positives

• The conversion of preferred stock into common stock simplifies the company's capital structure.

Risks

• The conversion of preferred stock to common stock may dilute existing shareholders' ownership.

Industry Context

Conversions of preferred stock to common stock are a common financial transaction, often used to simplify a company's capital structure or as part of a financing agreement.

Comparison to Industry Standards

• The conversion of preferred stock to common stock is a standard practice in corporate finance.
• Many companies, especially those in the biotech sector like Theriva Biologics, use convertible preferred stock as a financing tool.
• The conversion price of $1.22 per share is specific to this agreement and would need to be compared to other similar transactions to assess its favorability.

Stakeholder Impact

• The conversion of preferred stock to common stock may dilute the ownership of existing common shareholders.

Key Dates

Keywords

stock conversion, preferred stock, common stock, Theriva Biologics, equity